Sheaff Brock Investment Advisors LLC boosted its position in Intrexon Corporation (NYSE:XON) by 18.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 40,452 shares of the biotechnology company’s stock after purchasing an additional 6,210 shares during the quarter. Sheaff Brock Investment Advisors LLC’s holdings in Intrexon were worth $769,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Wells Fargo & Company MN increased its holdings in shares of Intrexon by 13.8% during the third quarter. Wells Fargo & Company MN now owns 118,462 shares of the biotechnology company’s stock valued at $2,252,000 after acquiring an additional 14,333 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Intrexon by 7,504.8% during the third quarter. JPMorgan Chase & Co. now owns 59,622 shares of the biotechnology company’s stock valued at $1,122,000 after acquiring an additional 58,838 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Intrexon by 493.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,258 shares of the biotechnology company’s stock valued at $271,000 after acquiring an additional 11,854 shares in the last quarter. Dynamic Technology Lab Private Ltd increased its holdings in shares of Intrexon by 127.0% during the third quarter. Dynamic Technology Lab Private Ltd now owns 24,640 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 13,783 shares in the last quarter. Finally, Macquarie Group Ltd. increased its holdings in shares of Intrexon by 25.7% during the third quarter. Macquarie Group Ltd. now owns 35,995 shares of the biotechnology company’s stock valued at $684,000 after acquiring an additional 7,353 shares in the last quarter. Institutional investors and hedge funds own 77.49% of the company’s stock.

XON has been the topic of several recent analyst reports. Zacks Investment Research downgraded shares of Intrexon from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Northland Securities restated a “buy” rating and set a $27.00 price objective on shares of Intrexon in a report on Friday, October 6th. Griffin Securities restated a “buy” rating and set a $55.00 price objective on shares of Intrexon in a report on Friday, October 6th. BidaskClub downgraded shares of Intrexon from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 22nd. Finally, JMP Securities restated an “outperform” rating and set a $42.00 price objective on shares of Intrexon in a report on Thursday, October 5th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Intrexon has a consensus rating of “Hold” and a consensus price target of $38.50.

Shares of Intrexon Corporation (NYSE:XON) traded down $0.13 during midday trading on Tuesday, reaching $13.42. The company had a trading volume of 1,315,100 shares, compared to its average volume of 1,142,171. Intrexon Corporation has a 52-week low of $10.26 and a 52-week high of $30.96. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.85 and a current ratio of 2.05.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/sheaff-brock-investment-advisors-llc-purchases-6210-shares-of-intrexon-corporation-xon/1745839.html.

About Intrexon

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Institutional Ownership by Quarter for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.